Literature DB >> 32890028

Myositis autoantibodies: recent perspectives.

Victoria Riddell1, Stefan Bagby1, Neil McHugh2.   

Abstract

PURPOSE OF REVIEW: To provide an overview of recent discoveries related to myositis-specific autoantibodies (MSAs) and assays used for their measurement. RECENT
FINDINGS: New autoantibody specificities have been reported including a MSA directed against eukaryotic initiation factor 3 and a myositis-associated autoantibody directed against heat shock factor 1. The association of anti-TIF1γ with cancer-associated dermatomyositis dependent on age has been confirmed in several large cohorts. Despite MSAs being almost entirely mutually exclusive, several myositis autoantigens are overexpressed in regenerating muscle and do not correlate with the corresponding MSA in any one patient. Further mechanisms may determine the final MSA specificity and are likely to include the need for autoantigen processing and presentation with adaptive T-cell help. The presence of CD4-positive T cells specific for histidyl tRNA synthetase protein in bronchial lavage fluid from antisynthetase patients lends support to this view. Finally, it is widely held that MSA do play an important role in clinical practice among some evidence and concern about commercial assay reliability.
SUMMARY: MSAs continue to provide important tools for clinical diagnosis and management as well as insights into disease mechanisms. Further improvement in the standardization and reliability of routine detection of MSAs is a high priority.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32890028     DOI: 10.1097/BOR.0000000000000742

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  4 in total

Review 1.  The Role of Autoantibody Testing in Modern Personalized Medicine.

Authors:  Cristiane Kayser; Lívia Almeida Dutra; Edgard Torres Dos Reis-Neto; Charlles Heldan de Moura Castro; Marvin J Fritzler; Luis Eduardo C Andrade
Journal:  Clin Rev Allergy Immunol       Date:  2022-03-04       Impact factor: 10.817

2.  Case Report: IgA Nephropathy in a Patient With Anti-Transcription Intermediary Factor-1γ Antibody-Positive Dermatomyositis.

Authors:  Suo Zhang; Yu-Lan Chen; Cui-Lian Liu; Jing-Yi Xie; Bao-Dong Sun; Dong-Zhou Liu
Journal:  Front Immunol       Date:  2022-02-03       Impact factor: 7.561

3.  Dermatomyositis post vaccine against SARS-COV2.

Authors:  Adolfo Camargo Coronel; Francisco Javier Jiménez Balderas; Horacio Quiñones Moya; Mario Raúl Hernández Zavala; Pedro Mandinabeitia Rodríguez; José Ramiro Hernández Vázquez; Sandy Zamora Zarco; Sergio De Jesús Aguilar Castillo
Journal:  BMC Rheumatol       Date:  2022-04-01

4.  Clinical, Serological, and Genetic Characteristics of a Hungarian Myositis-Scleroderma Overlap Cohort.

Authors:  Katalin Szabó; Levente Bodoki; Melinda Nagy-Vincze; Tibor Béldi; Anett Vincze; Erika Zilahi; József Varga; Gabriella Szűcs; Katalin Dankó; Zoltán Griger
Journal:  Biomed Res Int       Date:  2022-05-02       Impact factor: 3.246

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.